Ligand Pharmaceuticals Incorporated (LGND)
Payables turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Cost of revenue | US$ in thousands | 11,074 | 35,049 | 52,827 | 62,176 | 30,419 |
Payables | US$ in thousands | — | — | — | — | — |
Payables turnover | — | — | — | — | — |
December 31, 2024 calculation
Payables turnover = Cost of revenue ÷ Payables
= $11,074K ÷ $—K
= —
Based on the provided data, it appears that there is no specific information available for Ligand Pharmaceuticals Incorporated payables turnover for the years ending December 31, 2020 through December 31, 2024. This lack of data suggests that it is not possible to analyze the company's payables turnover ratio for these periods. Additional information or financial data would be required to assess and interpret the payables turnover efficiency of Ligand Pharmaceuticals Incorporated during these years.
Peer comparison
Dec 31, 2024
Company name
Symbol
Payables turnover
Ligand Pharmaceuticals Incorporated
LGND
—
Abbott Laboratories
ABT
—
AbbVie Inc
ABBV
—
ACADIA Pharmaceuticals Inc
ACAD
—
Alkermes Plc
ALKS
19.54
Amphastar P
AMPH
11.74
ANI Pharmaceuticals Inc
ANIP
—
Arcus Biosciences Inc
RCUS
8.33
Biomarin Pharmaceutical Inc
BMRN
—
Bristol-Myers Squibb Company
BMY
8.82
Catalyst Pharmaceuticals Inc
CPRX
—